Following the tour, both sides engaged in a strategic dialogue on industry trends. Dr. Bai briefed the guests on MOMED's development milestones, core R&D progress, and future financing plans, emphasizing the company's AI capabilities in accelerating drug discovery.

"Bio-Sincerity has decades of experience in chemical, biological, and advanced formulation development," noted Ms. Lou. "MOMED's AI technologies are revolutionizing traditional R&D models. The integration of AI and biopharmaceuticals represents the future, and we look forward to overcoming industry challenges through resource sharing and technological synergy."

Dr. Bai highlighted AI's role in enhancing efficiency across critical stages like target screening and compound optimization. "Our collaboration aligns perfectly in technological approaches and strategic visions," he added. "We aim to combine strengths in novel drug development and AI model innovation to drive breakthroughs."

The two companies identified opportunities for joint ventures in AI-aided drug design, R&D resource sharing, and global market expansion, marking the beginning of a comprehensive partnership.